Mississippi State Model Reproduces AFM Data on Copper-Zinc Effects in Amyloid-Beta Aggregation

Yarahmadian built a reaction-diffusion model that tracks metal-ion binding kinetics to amyloid-beta monomers and oligomers, then simulates nucleation and elongation steps under varying metal concentrations. The equations were solved numerically and compared directly to AFM-derived cluster-size distributions from in-vitro experiments; the simulated size histograms fell within 15% of measured values across the tested conditions. This agreement indicates the model captures rate-limiting steps that purely empirical screens often miss. The work complements ongoing chelation trials that have so far shown modest slowing of cognitive decline, suggesting targeted metal modulation remains a viable mechanistic lever rather than a dead end.

Existing literature on metal dyshomeostasis, including a 2021 meta-analysis in Alzheimer's & Dementia that linked elevated cortical copper to faster plaque accrual, supplies the biological priors the model now quantifies. The Mississippi State simulations further predict that selective zinc chelators could reduce fibril elongation by 30-40% at concentrations achievable in cerebrospinal fluid, a threshold not yet tested in human imaging studies. Prior coverage overlooked this quantitative prediction and its direct link to PET-tracer endpoints.

The chief limitation is reliance on simplified two-metal, one-protein kinetics that omit microglial clearance and vascular transport; an in-vivo validation cohort of at least 50 transgenic mice with longitudinal multiphoton imaging would materially strengthen causal claims. Next steps include coupling the framework to pharmacokinetic data from existing chelators to prioritize compounds for phase-I safety trials.